WSTAM
RMD icon

Wilbanks Smith & Thomas Asset Management’s ResMed RMD Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-91
Closed -$10K – 1100
2018
Q3 		$10K Buy
+91
New +$9.97K ﹤0.01% 1054

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's RMD Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of ResMed (RMD) in Q4 2018, closing a stake of 91 shares — an estimated $10K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in RMD in Q3 2018 and held it in 1 quarter. The position peaked at $10K in Q3 2018. 501 funds tracked by Wall St. Rank hold RMD as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining ResMed position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 91 ResMed shares in Q4 2018, an estimated $10K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in ResMed in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's ResMed position peaked at $10K in Q3 2018.
  • 501 funds tracked by Wall St. Rank held ResMed as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.